A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.
Unrelated mutations, when present in the blood, can lead to false positive results in men with advanced prostate cancer who are undergoing liquid biopsies.
Gomila et al. recently uploaded a study to the preprint server medRxiv* (November 2020), aiming to utilize MALDI-TOF MS to analyze the sera of patients infected with SARS-CoV-2 in a range of disease severity states.
In this interview, AZoLifeSciences speaks to Professor Kuhnle about his latest research which showed that a diet high in flavanols may lower blood pressure.
Researchers from Kumamoto University, Japan have proposed that cellular senescence variations during the aging process could lead to control of health and onset of age-related diseases.
Breast cancer is the most commonly occurring cancer for women around the world, and much effort has been spent in the development of therapies to treat this disease.
As medical professionals and scientists work to design new therapies for cancer, they come across a range of difficulties.
A team of researchers have discovered that a gut hormone, called ghrelin, is a crucial regulator of new nerve cells that form in the adult brain.
People who consume a diet including flavanol-rich foods and drinks, including tea, apples and berries, could lead to lower blood pressure, according to the first study using objective measures of thousands of UK residents' diet.
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
A global study has discovered the heart cells responsible for repairing the damage induced to this vital organ following infarction.
A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD), a life-threatening condition that can arise after hematopoietic stem cell transplantation (HSCT) for treatment of liquid cancers such as leukemia.
Imaging techniques could replace the need for invasive tissue biopsies in helping rapidly determine whether cancer treatments are working effectively, according to researchers at the University of Cambridge.
A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye.
Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.
AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.
Healthy people - especially women - with elevated levels of the heart failure marker NT-proBNP have a lower risk of developing type 2 diabetes.
Neutrophils are the warriors of the immune system. They are always ready to spring to action to help heal injuries or fight off disease. Unless, that is, something goes wrong in their developmental process.
University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies.
Because cancer is easier to successfully treat when it's caught early, a major goal in cancer research is to develop new ways to find tumors at early stages, before they start to spread. One approach that's being studied are liquid biopsies.
A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.